

ADVERTISEMENT

Heard the latest *The Lancet Infectious Diseases* podcast?



THE LANCET
Infectious Diseases

Home Journals ▾ Specialties ▾ The Lancet Clinic ▾ Global Health ▾ Multimedia ▾ Campaigns ▾ More ▾ Information for ▾

Submit a Paper ▾

THE LANCET
Infectious Diseases



Login | Register | Subscribe

Online First Current Issue All Issues Multimedia ▾ About the Journal

All Content

Search [Advanced Search](#)

[< Previous Article](#)




Online First

[Next Article >](#)

Access this article on [ScienceDirect](#) ▶

Articles

Oseltamivir, amantadine, and ribavirin combination antiviral therapy versus oseltamivir monotherapy for the treatment of influenza: a multicentre, double-blind, randomised phase 2 trial

Dr John H Beigel, MD  , Yajing Bao, MS, Joy Beeler, MPH, Weerawat Manosuthi, MD, Alex Slandzicki, MD, Sadia M Dar, MD, John Panuto, MD, Richard L Beasley, MD, Santiago Perez-Patrigion, MD, Gompol Suwanpimolkul, MD, Marcelo H Losso, MD, Natalie McClure, PhD, Dawn R Bozzolo, BA, Christopher Myers, PhD, H Preston Holley Jr, MD, Justin Hoopes, PhD, H Clifford Lane, MD, Michael D Hughes, PhD, Richard T Davey, MD on behalf of the  IRC003 Study Team†

† A complete list of the IRC003 Study Team members is provided the appendix

Published: 22 September 2017








DOI: [http://dx.doi.org/10.1016/S1473-3099\(17\)30476-0](http://dx.doi.org/10.1016/S1473-3099(17)30476-0) |



 Article Info

Summary **Full Text** Tables and Figures References Supplementary Material

Article Options

-  [PDF \(312 KB\)](#)
-  [Download Images\(.ppt\)](#)
-  [Email Article](#)
-  [Add to My Reading List](#)
-  [Export Citation](#)
-  [Create Citation Alert](#)
-  [Cited by in Scopus \(0\)](#)

Reader Comments

Please read the [commenting guidelines](#) before posting a comment.

Summary

Background

Influenza continues to have a substantial socioeconomic and health impact despite a long established vaccination programme and approved antivirals. Preclinical data suggest that combining antivirals might be more effective than administering oseltamivir alone in the treatment of influenza.

Methods

We did a randomised, double-blind, multicentre phase 2 trial of a combination of oseltamivir, amantadine, and ribavirin versus oseltamivir monotherapy with matching placebo for the treatment of influenza in 50 sites, consisting of academic medical centre clinics, emergency rooms, and private physician offices in the USA, Thailand, Mexico, Argentina, and Australia. Participants who were aged at least 18 years with influenza and were at increased risk of complications were randomly assigned (1:1) by an online computer-generated randomisation system to receive either oseltamivir (75 mg), amantadine (100 mg), and ribavirin (600 mg) combination therapy or oseltamivir monotherapy twice daily for 5 days, given orally, and participants were followed up for 28 days. Blinded treatment kits were used to achieve masking of patients and staff. The primary endpoint was the percentage of participants with virus detectable by PCR in nasopharyngeal swab at day 3, and was assessed in participants who were randomised, had influenza infection confirmed by the central laboratory on a baseline nasopharyngeal sample, and had received at least one dose of study drug. Safety assessment was done in all patients in the intention-to-treat population. This trial is registered with ClinicalTrials.gov, number [NCT01227967](https://clinicaltrials.gov/ct2/show/study/NCT01227967).

Findings

Between March 1, 2011, and April 29, 2016, 633 participants were randomly assigned to receive combination antiviral therapy (n=316) or monotherapy (n=317). Seven participants were excluded from analysis: three were not properly randomised, three withdrew from the study, and one was lost to follow-up. The primary analysis included 394 participants, excluding 47 in the pilot phase, 172 without confirmed influenza, and 13 without an endpoint sample. 80 (40.0%) of 200 participants in the combination group had detectable virus at day 3 compared with 97 (50.0%) of 194 (mean difference 10.0, 95% CI 0.2–19.8, p=0.046) in the monotherapy group. The most common adverse events were gastrointestinal-related disorders, primarily nausea (65 [12%] of 556 reported adverse events in the combination group vs 63 [11%] of 585 reported adverse events in the monotherapy group), diarrhoea (56 [10%] of 556 vs 64 [11%] of 585), and vomiting (39 [7%] of 556 vs 23 [4%] of 585). There was no benefit in multiple clinical secondary endpoints, such as median duration of symptoms (4.5 days in the combination group vs 4.0 days in the monotherapy group; p=0.21). One death occurred in the study in an elderly participant in the monotherapy group who died of cardiovascular failure 13 days after randomisation, judged by the site investigator as not related to study intervention.

Interpretation

Although combination treatment showed a significant decrease in viral shedding at day 3 relative to monotherapy, this difference was not associated with improved clinical benefit. More work is needed to understand why there was no clinical benefit when a difference in virological outcome was identified.

Funding

National Institute of Allergy and Infectious Diseases, National Institutes of Health, USA.

To read this article in full you will need to make a payment

Already registered? Please login.

[Login to existing account](#)

[Forgot password?](#)

Payment Options

- **Purchase this article for \$31.50 USD**
 - Online access for 24 hours
 - PDF version can be downloaded as your permanent record

Subscribe to The Lancet Infectious Diseases

[Purchase a subscription](#) to gain

Linked Articles

COMMENT

[Finding the right combination antiviral therapy for influenza](#)

Popular Articles

Most Read

Most Cited

Most read in *The Lancet Infectious Diseases* within the past 30 days.

CORRESPONDENCE

[Spread of a single multidrug resistant malaria parasite lineage \(*PfPailin*\) to Vietnam](#)

Vol. 17, No. 10

Published: October, 2017

ARTICLES

[Estimates of global, regional, and national morbidity, mortality, and aetiologies of diarrhoeal diseases: a systematic analysis for the Global Burden of Disease Study 2015](#)

Vol. 17, No. 9

Published: June 1, 2017

[Open Access](#)

ARTICLES

[Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory tract infections in 195 countries: a systematic analysis for the Global Burden of Disease Study 2015](#)

Published: August 23, 2017

[Open Access](#)

ARTICLES

[Impact of the introduction of pneumococcal conjugate vaccination on pneumonia in The Gambia: population-based surveillance and case-control studies](#)

Vol. 17, No. 9

Published: June 7, 2017

[Open Access](#)

ARTICLES

[Diagnostic accuracy of Xpert MTB/RIF Ultra for tuberculous meningitis in HIV-infected adults: a prospective cohort study](#)

Published: September 14, 2017

Register

[Create a new account](#)

The Lancet Choice

Access any 5 articles from The Lancet family of journals

- Full text and PDF access to 5 paywall articles of your choice
- Valid for 365 days from date of purchase
- [Find out more about The Lancet Choice](#)

access to this and all other articles in this journal.

Options include:

- [Personal online only subscription](#)

Institutional Access

[Visit ScienceDirect](#) to see if you have access via your institution.

Already a print subscriber?

[Claim online access](#)

Have a free trial code?

[Activate your free trial](#)

[Open Access](#)

The Lancet Choice



The Lancet Choice is a new payment option that gives you the freedom and flexibility to access any 5 premium articles of your choice from across *The Lancet* family of journals - all for a one-off payment of \$49.00 USD.

Simply purchase your Lancet Choice pass from the Summary or Full Text page of an article you wish to access. This will count as the first of 5 article credits, or 'Allowances', and you can use your 4 remaining Allowances to access other articles from any of *The Lancet* journals.

[Find out more about The Lancet Choice](#)

The Lancet Journals

The Lancet
 The Lancet Child & Adolescent Health
 The Lancet Diabetes & Endocrinology
 The Lancet Gastroenterology & Hepatology
 The Lancet Global Health
 The Lancet Haematology

The Lancet HIV
 The Lancet Infectious Diseases
 The Lancet Neurology
 The Lancet Oncology
 The Lancet Planetary Health
 The Lancet Psychiatry
 The Lancet Public Health
 The Lancet Respiratory Medicine
 EBioMedicine

Information & Support

About Us
 Information for Authors
 Information for Readers
 The Lancet Careers
 Customer Service
 Contact Us
 Privacy Policy
 Terms and Conditions

Subscription

Your Account
 Subscription Options
 Existing Print Subscribers

Copyright © 2017 Elsevier Limited except certain content provided by third parties.

The Lancet is a trade mark of RELX Intellectual Properties SA, used under license.

The Lancet.com website is operated by Elsevier Inc. The content on this site is intended for health professionals.

Cookies are set by this site. To decline them or learn more, visit our Cookies page.

The Lancet demonstrates its commitment to accessibility by enabling access and optimising the experience for individuals with disabilities and impairments.

